FIELD: medicine, cardiology, angiology and cardiac surgery.
SUBSTANCE: invention can be used to predict adverse cardiovascular events. The concentration of visfatin in the blood serum is determined 10 days after coronary artery bypass grafting by enzyme immunoassay using human visfatin EIA RayBiotech. With a concentration of visfatin of 14.05 ng/ml or more, a high risk of developing adverse cardiovascular events is predicted.
EFFECT: method allows to effectively predict adverse cardiovascular events and reasonably distribute patients into risk groups for the use of additional preventive and therapeutic measures in high-risk groups.
1 cl, 1 tbl, 3 ex
